多西他赛是新的紫杉类抗癌药物。
早期应用培美曲赛对OS是获益的而不是多西他赛；
OS benefit is obtained with early use of pemetrexed but not docetaxel;
目的建立了HPLC法测定注射用多西他赛的含量。
Objective HPLC method was established for injection of docetaxel content.
数据表明多西他赛(T)可能增加PF方案的有效性。
Data suggest that docetaxel (t) may add to the efficacy of PF.
结果测定多西他赛注射液样品中多西他赛含量为标示量的97.4%。
Results Determines of docetaxel quantity 97.4% to sample of the indication.
方法：采用改良薄膜分散法结合冷冻干燥工艺制备多西他赛脂质体冻干粉；
Methods: Docetaxel liposomes were prepared by modified film dispersion-high pressure homogenization and lyophilization.
目的评价国产多西他赛联合奥沙利铂作为铂类耐药的晚期卵巢上皮癌解救化疗的疗效和毒性。
Objective To evaluate the efficacy and toxicity of docetaxel plus oxaliplatin in the treatment of platinum resistance advanced epithelia ovary cancer.
目的观察多西他赛联合顺铂和5 -氟脲嘧啶方案治疗转移性食管癌的近期疗效和毒副反应。
Objective to evaluate the recent efficacy and toxicity of docetaxel combined with cisplatin and 5-fu in the treatment of patients with metastatic esophageal cancer.
目的：探讨多西他赛(艾素)每周给药联合卡铂治疗晚期非小细胞肺癌的临床疗效和不良反应。
Objective: To investigate the efficacy and safety of docetaxel administrated weekly plus carboplatin in the treatment of patients with advanced non-small-cell lung cancer (NSCLC).
这种研究发现证实了来自Fidias等关于多西他赛的研究结果，而且4项大型的临床研究都有相似的试验设计。
Such findings confirm the data from Fidias et al with respect to docetaxel, and the 4 studies had a similar design.
中位进展时间—首要观察终点—与所有单用多西他赛方案(7.0月)相比联合方案组的中位进展时间(9.8月)明显延长。
The median time to progression - the primary end point - was significantly longer (9.8 months) among those on the combination, compared to those on docetaxel alone (7.0 months).
中位进展时间—首要观察终点—与所有单用多西他赛方案(7.0月)相比联合方案组的中位进展时间(9.8月)明显延长。
The median time to progression - the primary end point - was significantly longer (9.8 months) among those on the combination, compared to those on docetaxel alone (7.0 months).
应用推荐